Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping
- PMID: 32980440
- DOI: 10.1016/j.pharmthera.2020.107689
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping
Abstract
Enzymes of the UDP-glucuronosyltransferase (UGT) superfamily contribute to the elimination of drugs from almost all therapeutic classes. Awareness of the importance of glucuronidation as a drug clearance mechanism along with increased knowledge of the enzymology of drug and chemical metabolism has stimulated interest in the development and application of approaches for the characterisation of human drug glucuronidation in vitro, in particular reaction phenotyping (the fractional contribution of the individual UGT enzymes responsible for the glucuronidation of a given drug), assessment of metabolic stability, and UGT enzyme inhibition by drugs and other xenobiotics. In turn, this has permitted the implementation of in vitro - in vivo extrapolation approaches for the prediction of drug metabolic clearance, intestinal availability, and drug-drug interaction liability, all of which are of considerable importance in pre-clinical drug development. Indeed, regulatory agencies (FDA and EMA) require UGT reaction phenotyping for new chemical entities if glucuronidation accounts for ≥25% of total metabolism. In vitro studies are most commonly performed with recombinant UGT enzymes and human liver microsomes (HLM) as the enzyme sources. Despite the widespread use of in vitro approaches for the characterisation of drug and chemical glucuronidation by HLM and recombinant enzymes, evidence-based guidelines relating to experimental approaches are lacking. Here we present evidence-based strategies for the characterisation of drug and chemical glucuronidation in vitro, and for UGT reaction phenotyping. We anticipate that the strategies will inform practice, encourage development of standardised experimental procedures where feasible, and guide ongoing research in the field.
Keywords: Albumin effect; Drug-drug interactions; Enzyme assay; Enzyme kinetics; Glucuronidation; In vitro – In vivo extrapolation; Incubation conditions; Inhibitor selectivity; Non-specific binding; Reaction phenotyping; Substrate selectivity; UDP-Glucuronosyltransferase.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.Drug Metab Rev. 2010 Feb;42(1):196-208. doi: 10.3109/03602530903210716. Drug Metab Rev. 2010. PMID: 19795925
-
In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.Biochem Pharmacol. 2006 May 28;71(11):1531-9. doi: 10.1016/j.bcp.2005.12.019. Epub 2006 Feb 7. Biochem Pharmacol. 2006. PMID: 16455060 Review.
-
The effects of UDP-sugars, UDP and Mg2+on uridine diphosphate glucuronosyltransferase activity in human liver microsomes.Xenobiotica. 2018 Sep;48(9):882-890. doi: 10.1080/00498254.2017.1376260. Epub 2017 Sep 26. Xenobiotica. 2018. PMID: 28868965
-
Highly selective N-glucuronidation of four piperazine-containing drugs by UDP-glucuronosyltransferase 2B10.Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):989-998. doi: 10.1080/17425255.2018.1505862. Epub 2018 Aug 2. Expert Opin Drug Metab Toxicol. 2018. PMID: 30049229
-
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance.Pharmacol Ther. 2023 Aug;248:108459. doi: 10.1016/j.pharmthera.2023.108459. Epub 2023 May 30. Pharmacol Ther. 2023. PMID: 37263383 Review.
Cited by
-
MetaTREE, a Novel Database Focused on Metabolic Trees, Predicts an Important Detoxification Mechanism: The Glutathione Conjugation.Molecules. 2021 Apr 6;26(7):2098. doi: 10.3390/molecules26072098. Molecules. 2021. PMID: 33917533 Free PMC article.
-
Inhibitory effects of Kratom constituents, mitragynine and 7-hydroxymitragynine, on 4-methylumbelliferone glucuronidation by human UDP-glucuronosyltransferases.Toxicol Rep. 2025 Feb 10;14:101951. doi: 10.1016/j.toxrep.2025.101951. eCollection 2025 Jun. Toxicol Rep. 2025. PMID: 40026476 Free PMC article.
-
Comparison of Relative Activity versus Relative Expression Factors (RAF versus REF) in Predicting Glucuronidation Mediated Drug Clearance Using Recombinant UGTs.Pharm Res. 2024 Aug;41(8):1621-1630. doi: 10.1007/s11095-024-03750-x. Epub 2024 Aug 6. Pharm Res. 2024. PMID: 39107514
-
Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et al.Clin Pharmacol Ther. 2025 Aug;118(2):301-303. doi: 10.1002/cpt.3734. Epub 2025 May 26. Clin Pharmacol Ther. 2025. PMID: 40418110 Free PMC article. No abstract available.
-
Aminobenzotriazole inhibits and induces several key drug metabolizing enzymes complicating its utility as a pan CYP inhibitor for reaction phenotyping.Clin Transl Sci. 2024 Mar;17(3):e13746. doi: 10.1111/cts.13746. Clin Transl Sci. 2024. PMID: 38501263 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials